Lead Product(s): Doxorubicin peptide conjugate
Therapeutic Area: Oncology
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2020
Both TH1902 (docetaxel peptide conjugate) and TH1904 (doxorubicin peptide conjugate), are more effective and better tolerated in animal models than two commonly-used ovarian cancer treatments.